Rituximab is an anti-CD20 monoclonal antibody with considerable potential in 
dermatology due to an increase in off-label indications. Chronic 
graft-versus-host disease and pemphigus vulgaris are two of the most promising 
indications for off-label use of rituximab. It is a generally safe alternative 
that should be considered when traditional therapy with corticosteroids or 
immunosuppressants has failed or caused significant intolerance. Currently, 
rituximab is only FDA-approved for treatment of follicular and diffuse large 
B-cell non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic 
leukemia, granulomatosis with polyangiitis (formerly Wegener's granulomatosis) 
and microscopic polyangiitis. Herein, off-label uses of rituximab and its 
efficacy in the treatment of cutaneous diseases are reviewed.